XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 20 - Stock Options

9 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

20.

STOCK OPTIONS

On September 14, 2017, the Company’s Board of Directors unanimously adopted the 2017 Employee Stock Option Plan (the “2017 Employee Plan”) and the 2017 Directors Equity Incentive Plan (the “2017 Directors Plan”) each of which was approved by the shareholders on December 4, 2017.

Assumptions

The fair value for the stock options granted to both employees and directors was estimated using the Black-Scholes option pricing model with the following weighted average assumptions, assuming:

●	An expected life varying from 2.50 to 3.25 years, calculated in accordance with the guidance provided in SEC Staff bulletin No. 110 for plain vanilla options using the simplified method, since the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term
●	A risk-free interest rate varying from 0.11% to 4.59% (2024: 0.11% to 4.59%);
●	No expected dividend payments; and
●	Expected volatility of 46.7% to 73.9% (2024: 53.8% to 73.85%).

2017 Employee Stock Option Plan

The Company’s 2017 Employee Plan permits the grant of stock options to its employees covering up to an aggregate of 300,000 shares of Common Stock. In December 2021, the Company’s Board of Directors approved an amendment to the 2017 Employee Plan to increase the shares covered thereby from 300,000 shares to an aggregate of 600,000 shares, which amendment was approved by the Company’s shareholders at the annual meeting held in December 2021.

Under the 2017 Employee Plan, all options must be granted with an exercise price of no less than fair value as of the grant date and the options granted must be exercisable within a maximum of ten years after the date of grant, or such lesser period of time as is set forth in the stock option agreements. The options may be exercisable (a) immediately as of the effective date of the stock option agreement granting the option, or (b) in accordance with a schedule related to the date of the grant of the option, the date of first employment, or such other date as may be set by the Compensation Committee. Generally, options granted under the 2017 Employee Plan are exercisable within five years after the date of grant and vest over the period as follows: 25% vesting on the grant date and the remaining balance vesting in equal installments on the next three succeeding anniversaries of the grant date. The share-based compensation will be recognized in terms of the grade method on a straight-line basis for each separately vesting portion of the award. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the 2017 Employee Plan).

During the nine-month period ended March 31, 2025, there were 80,000 stock options granted and 2,500 stock options were exercised under 2017 Employee Plan. The Company recognized $209 in stock-based compensation expense during the nine months ended March 31, 2025.

During the nine-month period ended March 31, 2024, there were 122,500 stock options granted and 64,625 stock options were exercised under 2017 Employee Plan. The Company recognized $208 in stock-based compensation expense during the nine months ended March 31, 2024.

As of March 31, 2025, there were vested stock options granted under the 2017 Employee Plan covering a total of 210,750 shares of Common Stock. The weighted-average exercise price was $5.59 and the weighted average remaining contractual term was 2.60 years.

As of March 31, 2024, there were vested stock options granted under the 2017 Employee Plan covering a total of 136,250 shares of Common Stock. The weighted-average exercise price was $5.57 and the weighted average remaining contractual term was 3.12 years.

A summary of option activities under the 2017 Employee Plan during the nine months ended March 31, 2025, is presented as follows:

										Weighted
										Average
						Weighted				Remaining
						Average				Contractual				Aggregate
						Exercise				Term				Intrinsic
		Options				Price				(Years)				Value

Outstanding at July 1, 2024			270,750			$	5.35				3.43			$	268
Granted			80,000				6.20				-				-
Exercised			(2,500	)			4.97				-				-
Forfeited or expired			-				-				-				-
Outstanding at March 31, 2025			348,250				5.55				3.13				243
Exercisable at March 31, 2025			210,750				5.59				2.60				160

A summary of the status of the Company’s non-vested employee stock options during the nine months ended March 31, 2025, is presented below:

						Weighted
						Average
						Grant-Date
		Options				Fair Value

Non-vested at July 1, 2024			134,500			$	5.12
Granted			80,000				6.30
Vested			(77,000	)			-
Non-vested at March 31, 2025			137,500				5.47

A summary of option activities under the 2017 Employee Plan during the nine months ended March 31, 2024, is presented as follows:

										Weighted
										Average
						Weighted				Remaining
						Average				Contractual				Aggregate
						Exercise				Term				Intrinsic
		Options				Price				(Years)				Value

Outstanding at July 1, 2023			216,375			$	4.89				2.92			$	140
Granted			122,500				4.96				-				-
Exercised			(64,625	)			3.14				-				-
Forfeited or expired			(3,500	)			3.75				-				-
Outstanding at March 31, 2024			270,750			$	5.35				3.68			$	331
Exercisable at March 31, 2024			136,250			$	5.57				3.12			$	150

A summary of the status of the Company’s non-vested employee stock options during the nine months ended March 31, 2024, is presented below:

						Weighted
						Average
						Grant-Date
		Options				Fair Value

Non-vested at July 1, 2023			81,750			$	5.53
Granted			122,500				4.96
Vested			(69,750	)			-
Non-vested at March 31, 2024			134,500			$	5.12

2017 Directors Equity Incentive Plan

The 2017 Directors Plan permits the grant of options to its directors in the form of non-qualified options and restricted stock, and initially covered up to an aggregate of 300,000 shares of Common Stock. In September 2020, the Company’s Board of Directors approved an amendment to the 2017 Directors Plan to increase the shares covered thereby from 300,000 shares to an aggregate of 600,000 shares, which amendment was approved by the Company’s shareholders at the annual meeting held in December 2020. In October 2023, the Company’s Board of Directors approved an amendment to the 2017 Directors Plan to increase the shares covered thereby from 600,000 shares to an aggregate of 900,000 shares, which amendment was approved by the Company’s shareholders at the annual meeting held in December 2023.

Under the 2017 Directors Plan, the exercise price of the non-qualified options is required to be 100% of the fair value of the underlying shares on the grant date. The options have five-year contractual terms and are exercisable immediately as of the grant date.

During the nine-month period ended March 31, 2025, the Company granted 100,000 stock options under the 2017 Directors Plan. There were 60,000 stock options exercised and the Company recognized $204 in stock-based compensation expense during the nine months ended March 31, 2025.

During the nine-month period ended March 31, 2024, the Company granted 100,000 stock options and 49,000 stock options were exercised under the 2017 Directors Plan. The Company recognized $220 in stock-based compensation expense during the nine months ended March 31, 2024.

As all the stock options granted under the 2017 Directors Plan vest immediately on the date of grant, there were no unvested stock options granted under the 2017 Directors Plan as of March 31, 2025, or March 31, 2024.

As of March 31, 2025, there were vested stock options granted under the 2017 Directors Plan covering a total of 471,000 shares of Common Stock. The weighted average exercise price was $5.80 and the weighted average remaining contractual term was 3.01 years.

As of March 31, 2024, there were vested stock options granted under the 2017 Directors Plan covering a total of 471,000 shares of Common Stock. The weighted average exercise price was $5.08 and the weighted average remaining contractual term was 2.87 years.

A summary of option activities under the 2017 Directors Plan during the nine months ended March 31, 2025, is presented as follows:

										Weighted
										Average
						Weighted				Remaining
						Average				Contractual				Aggregate
						Exercise				Term				Intrinsic
		Options				Price				(Years)				Value

Outstanding at July 1, 2024			431,000			$	5.24				2.88			$	531
Granted			100,000				-				-				-
Exercised			(60,000	)			-				-				-
Forfeited or expired			-				-				-				-
Outstanding at March 31, 2025			471,000				5.80				3.01				291
Exercisable at March 31, 2025			471,000			$	5.80				3.01			$	291

A summary of option activities under the 2017 Directors Plan during the nine months ended March 31, 2024, is presented as follows:

										Weighted
										Average
						Weighted				Remaining
						Average				Contractual				Aggregate
						Exercise				Term				Intrinsic
		Options				Price				(Years)				Value

Outstanding at July 1, 2023			420,000			$	4.91				2.91			$	309
Granted			100,000				5.01				-				-
Exercised			(49,000	)			3.51				-				-
Forfeited or expired			-				-				-				-
Outstanding at March 31, 2024			471,000			$	5.08				2.87			$	744
Exercisable at March 31, 2024			471,000			$	5.08				2.87			$	744